Trial · NCT00616239
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
NCT00616239, Phase 4, Completed, University of Texas Southwestern Medical Center; results first posted 2013-12-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women. Trials, record NCT00616239. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00616239
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
- NCT number
- NCT00616239
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Melasma
- Interventions
- 20-30% Salicylic Acid peels to the right side of the face, 20-30% Salicylic Acid peels to the left side of the face
- First posted
- 2008-02-15
- Last updated
- 2020-08-10
- Results first posted
- 2013-12-30
- Limitations and caveats
- Two subjects did not complete the study were unable to come in for visits because of scheduling difficulties and had no adverse effects at the time of discontinuation.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Showing Improvement of Melasma Based on Mexameter Readings | 14 weeks | Improvement of melasma on the peel side using mexameter reading |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Showing Improvement of Melasma Based on Mexameter Readings | 14 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Showing Improvement of Melasma Based on Mexameter Readings | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 18 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 20 | |
| Overall Study | COMPLETED | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 18 | |
| Overall Study | NOT COMPLETED | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 2 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Erythema | Skin and subcutaneous tissue disorders | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 4 | 20 | 4 |
| other | Burning | Skin and subcutaneous tissue disorders | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 4 | 20 | 4 |
| other | Peeling | Skin and subcutaneous tissue disorders | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 4 | 20 | 4 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 0 | 20 |
| Total, other adverse events | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 4 | 20 |
| Total, serious adverse events | 20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00616239
GET https://conductscience.org/api/trials/v1/NCT00616239/registered